Bio-Path Holdings Inc BPTH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BPTH is a good fit for your portfolio.
News
-
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
-
Bio-Path Holdings Expands Global Patent Portfolio
-
Bio-Path Holdings shares sink 6% after deal for at-the-market offering
-
Bio-Path Holdings Provides 2024 Clinical and Operational Update
-
Bio-Path Holdings Reports Full Year 2023 Financial Results
-
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024
-
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
Trading Information
- Previous Close Price
- $3.24
- Day Range
- $3.56–7.67
- 52-Week Range
- $2.71–44.80
- Bid/Ask
- $4.62 / $4.73
- Market Cap
- $3.17 Mil
- Volume/Avg
- 305,890 / 1.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 10
- Website
- https://www.biopathholdings.com
Valuation
|
Metric
|
BPTH
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.27 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BPTH
|
|---|---|
Quick Ratio | 0.55 |
Current Ratio | 1.60 |
Interest Coverage | — |
Quick Ratio
BPTH
Profitability
|
Metric
|
BPTH
|
|---|---|
Return on Assets (Normalized) | −180.14% |
Return on Equity (Normalized) | −240.86% |
Return on Invested Capital (Normalized) | −235.14% |
Return on Assets
BPTH
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ccswxcqgg | Hbxfq | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kzxrljsws | Jmgztx | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cngzgmhx | Frkxzy | $98.1 Bil | |
MRNA
| Moderna Inc | Dmwrdvsx | Wffqw | $39.1 Bil | |
ARGX
| argenx SE ADR | Mpvmjzpd | Txq | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Lmkvysv | Dnby | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gqvqxlns | Sskkg | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ffvlnxfc | Rkscvy | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gzbtbrln | Jyfml | $12.5 Bil | |
INCY
| Incyte Corp | Fjjrmhpm | Xvkxl | $11.9 Bil |